This database contains 1433 studies, archived under the term: ""
Click here to filter this large number of results.
Hormone levels and cognitive function in postmenopausal midlife women
Ryan, Joanne,
Stanczyk, Frank Z.,
Dennerstein, Lorraine,
Mack, Wendy J.,
Clark, Margaret S.,
Szoeke, Cassandra,
Kildea, Daniel,
Henderson, Victor W.
Gonadal hormones may influence cognitive function. Postmenopausal midlife women in the population-based Melbourne Women’s Midlife Health Project cohort were administered a comprehensive battery of neuropsychological tests on two occasions 2 years apart. Participants (n = 148, mean age 60 years) had undergone natural menopause and were not using hormone therapy. Estrone, total and free estradiol, […]
Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment
Rondanelli, Mariangela,
Opizzi, Annalisa,
Faliva, Milena,
Mozzoni, Marco,
Antoniello, Neldo,
Cazzola, Roberta,
Savarè, Rita,
Cerutti, Renata,
Grossi, Enzo,
Cestaro, Benvenuto
Age-related changes in nutritional status can play an important role in brain functioning. Specific nutrient deficiencies in the elderly may exacerbate pathological processes in the brain. Consequently, the potential of nutritional intervention to prevent or delay cognitive impairment and the development of dementia is an important topic. A randomized, double-blind, placebo-controlled trial has been performed […]
Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer’s disease
Portelius, Erik,
Zetterberg, Henrik,
Dean, Robert A.,
Marcil, Alexandre,
Bourgeois, Philippe,
Nutu, Magdalena,
Andreasson, Ulf,
Siemers, Eric,
Mawuenyega, Kwasi G.,
Sigurdson, Wendy C.,
May, Patrick C.,
Paul, Steven M.,
Holtzman, David M.,
Blennow, Kaj,
Bateman, Randall J.
Amyloid-β (Aβ) producing enzymes are key targets for disease-modifying Alzheimer’s disease (AD) therapies since Aβ trafficking is at the core of AD pathogenesis. Development of such drugs might benefit from the identification of markers indicating in vivo drug effects in the central nervous system. We have previously shown that Aβ(1-15) is produced by concerted β-and […]
Ageing in general practice (AGP) trial: a cluster randomised trial to examine the effectiveness of peer education on GP diagnostic assessment and management of dementia
Pond, Constance D.,
Brodaty, Henry,
Stocks, Nigel P.,
Gunn, Jane,
Marley, John,
Disler, Peter,
Magin, Parker,
Paterson, Nerida,
Horton, Graeme,
Goode, Susan,
Paine, Bronwen,
Mate, Karen E.
Background: Dementia is increasing in prevalence as the population ages. An earlier rather than later diagnosis allows persons with dementia and their families to plan ahead and access appropriate management. However, most diagnoses are made by general practitioners (GPs) later in the course of the disease and are associated with management that is poorly adherent […]
Persons with Alzheimer’s disease make phone calls independently using a computer-aided telephone system
Perilli, Viviana,
Lancioni, Giulio E.,
Singh, Nirbhay N.,
O’Reilly, Mark F.,
Sigafoos, Jeff,
Cassano, Germana,
Cordiano, Noemi,
Pinto, Katia,
Minervini, Mauro G.,
Oliva, Doretta
This study assessed whether four patients with a diagnosis of Alzheimer’s disease could make independent phone calls via a computer-aided telephone system. The study was carried out according to a non-concurrent multiple baseline design across participants. All participants started with baseline during which the telephone system was not available, and continued with intervention in which […]
The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study
Padala, Kalpana P.,
Padala, Prasad R.,
McNeilly, Dennis P.,
Geske, Jenenne A.,
Sullivan, Dennis H.,
Potter, Jane F.
Background: Statins are well-known for their cardiovascular benefits. However, the cognitive effects of statins are not well understood. We hypothesized that individuals with preexisting dementia would be more vulnerable to statin-related cognitive effects.; Objective: The aim of this study was to evaluate the impact on cognition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin) discontinuation and rechallenge […]
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, Susanne,
Deptula, Dennis,
Thurfjell, Lennart,
Barkhof, Frederik,
Bohrmann, Bernd,
Brooks, David J.,
Klunk, William E.,
Ashford, Elizabeth,
Yoo, Kisook,
Xu, Zhi-Xin,
Loetscher, Hansruedi,
Santarelli, Luca
Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]